Physician profile
Samuel E Ottong
NPI 1972706174
$4,424.94
in general payments reported to CMS, 2019-2025
21 companies · $834 in 2025
The $834 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $528 · 2021: $816 · 2022: $424 · 2023: $370 · 2024: $878 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $918.24 | 2019-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $885.30 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $626.41 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $556.74 | 2020-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $422.93 | 2020-2024 | Mounjaro |
| Abbvie INC. | $228.10 | 2021-2025 | |
| Lundbeck LLC | $122.43 | 2025 | Vyepti |
| Kowa Pharmaceuticals America, INC. | $115.95 | 2023-2025 | Seglentis, Zoryve |
| Paratek Pharmaceuticals, INC. | $101.90 | 2024-2025 | Nuzyra |
| Azurity Pharmaceuticals, INC. | $75.76 | 2023-2024 | Horizant, Adthyza, Edarbyclor |
| Amgen INC. | $68.55 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.98 | 2019-2020 | |
| Amarin Pharma, INC. | $46.16 | 2021 | |
| Allergan, INC. | $31.06 | 2020 | |
| Arbor Pharmaceuticals, INC. | $29.90 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $28.83 | 2023 | |
| Scilex Pharmaceuticals INC. | $24.56 | 2019 | |
| Exact Sciences Corporation | $23.33 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $21.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Ottong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.